Aberrant SOCS3 Promoter Methylation As a Noninvasive Diagnostic Biomarker for Locally Advanced Prostate Cancer

Overview

Journal Medeni Med J

Publisher Galenos Publishing House

Specialty General Medicine

Date 2020 Aug 1

PMID 32733758

Citations 2

Authors

Berna Demircan Tan

Turgay Turan

Burcu Yucel

Sedef Altundag Kara

Seda Salman Yilmaz

Asif Yildirim

Affiliations

Soon will be listed here.

Abstract

Objective: The aim of this study was to investigate the promoter methylation status of Rasassociated domain family 1A (RASSF1A), O-6-methylguanine-DNA methyltransferase (MGMT), Phosphatase with tensin homology (PTEN) and Suppressor of cytokine signaling 3 (SOCS3) tumor suppressor genes and evaluate the clinical utility of these genes as noninvasive, blood-based epigenetic biomarkers for the diagnosis of Prostate Cancer (PCa).

Method: A total of 41 consecutive patients and 10 healthy control groups were enrolled in the study. Pyrosequencing was performed to analyze the methylation levels of the promoter regions of the four tumor suppressor genes in patients compared to healthy controls.

Results: The promoter methylation levels of RASSF1A, MGMT, PTEN and SOCS3 did not differ between the patient and control groups. However, SOCS3 promoter methylation level was significantly higher for patients having locally advanced PCa compared to those having localizedPCa (p<0.05).

Conclusion: Our results indicated that SOCS3 could be a useful, noninvasive blood-based epigenetic biomarker for the diagnosis of locally advanced PCa.

Citing Articles

Pomegranate Peel Extract Sensitizes Hepatocellular Carcinoma Cells to Ionizing Radiation, Induces Apoptosis and Inhibits MAPK, JAK/STAT3, β-Catenin/NOTCH, and SOCS3 Signaling.

Elbakry M, Elbakary N, Hagag S, Hemida E Integr Cancer Ther. 2023; 22:15347354221151021.

PMID: 36710483 PMC: 9893067. DOI: 10.1177/15347354221151021.

SOCS3 Acts as an Onco-immunological Biomarker With Value in Assessing the Tumor Microenvironment, Pathological Staging, Histological Subtypes, Therapeutic Effect, and Prognoses of Several Types of Cancer.

Dai L, Tao Y, Shi Z, Liang W, Hu W, Xing Z Front Oncol. 2022; 12:881801.

PMID: 35600392 PMC: 9122507. DOI: 10.3389/fonc.2022.881801.

References

Ge Y, Xu L, Jia R, Xu Z, Feng Y, Wu R . The association between RASSF1A promoter methylation and prostate cancer: evidence from 19 published studies. Tumour Biol. 2013; 35(4):3881-90. DOI: 10.1007/s13277-013-1515-3. View

Martin N . New developments in prostate cancer biomarkers. Curr Opin Oncol. 2016; 28(3):248-52. DOI: 10.1097/CCO.0000000000000279. View

Mahon K, Qu W, Lin H, Spielman C, Cain D, Jacobs C . Serum Free Methylated Glutathione S-transferase 1 DNA Levels, Survival, and Response to Docetaxel in Metastatic, Castration-resistant Prostate Cancer: Post Hoc Analyses of Data from a Phase 3 Trial. Eur Urol. 2018; 76(3):306-312. DOI: 10.1016/j.eururo.2018.11.001. View

Blute Jr M, Damaschke N, Jarrard D . The epigenetics of prostate cancer diagnosis and prognosis: update on clinical applications. Curr Opin Urol. 2014; 25(1):83-8. PMC: 5526656. DOI: 10.1097/MOU.0000000000000132. View

Moschini M, Spahn M, Mattei A, Cheville J, Karnes R . Incorporation of tissue-based genomic biomarkers into localized prostate cancer clinics. BMC Med. 2016; 14:67. PMC: 4820857. DOI: 10.1186/s12916-016-0613-7. View

Luo J, Ding Y, Chen R, Michalopoulos G, Nelson J, Tseng G . Genome-wide methylation analysis of prostate tissues reveals global methylation patterns of prostate cancer. Am J Pathol. 2013; 182(6):2028-36. PMC: 3668028. DOI: 10.1016/j.ajpath.2013.02.040. View

Kim Y, Yoon H, Kim S, Kim Y, Kim E, Kim I . EFEMP1 as a novel DNA methylation marker for prostate cancer: array-based DNA methylation and expression profiling. Clin Cancer Res. 2011; 17(13):4523-30. DOI: 10.1158/1078-0432.CCR-10-2817. View

Jeronimo C, Henrique R, Hoque M, Mambo E, Ribeiro F, Varzim G . A quantitative promoter methylation profile of prostate cancer. Clin Cancer Res. 2004; 10(24):8472-8. DOI: 10.1158/1078-0432.CCR-04-0894. View

Martignano F, Gurioli G, Salvi S, Calistri D, Costantini M, Gunelli R . GSTP1 Methylation and Protein Expression in Prostate Cancer: Diagnostic Implications. Dis Markers. 2016; 2016:4358292. PMC: 4995330. DOI: 10.1155/2016/4358292. View

10.

Yegnasubramanian S, Kowalski J, Gonzalgo M, Zahurak M, Piantadosi S, Walsh P . Hypermethylation of CpG islands in primary and metastatic human prostate cancer. Cancer Res. 2004; 64(6):1975-86. DOI: 10.1158/0008-5472.can-03-3972. View

11.

Whang Y, Wu X, Suzuki H, Reiter R, Tran C, Vessella R . Inactivation of the tumor suppressor PTEN/MMAC1 in advanced human prostate cancer through loss of expression. Proc Natl Acad Sci U S A. 1998; 95(9):5246-50. PMC: 20246. DOI: 10.1073/pnas.95.9.5246. View

12.

Wu Y, Davison J, Qu X, Morrissey C, Storer B, Brown L . Methylation profiling identified novel differentially methylated markers including OPCML and FLRT2 in prostate cancer. Epigenetics. 2016; 11(4):247-58. PMC: 4889305. DOI: 10.1080/15592294.2016.1148867. View

13.

Brait M, Banerjee M, Maldonado L, Ooki A, Loyo M, Guida E . Promoter methylation of MCAM, ERα and ERβ in serum of early stage prostate cancer patients. Oncotarget. 2017; 8(9):15431-15440. PMC: 5362497. DOI: 10.18632/oncotarget.14873. View

14.

Handle F, Erb H, Luef B, Hoefer J, Dietrich D, Parson W . SOCS3 Modulates the Response to Enzalutamide and Is Regulated by Androgen Receptor Signaling and CpG Methylation in Prostate Cancer Cells. Mol Cancer Res. 2016; 14(6):574-85. DOI: 10.1158/1541-7786.MCR-15-0495. View

15.

Dasgupta P, Baade P, Aitken J, Ralph N, Chambers S, Dunn J . Geographical Variations in Prostate Cancer Outcomes: A Systematic Review of International Evidence. Front Oncol. 2019; 9:238. PMC: 6463763. DOI: 10.3389/fonc.2019.00238. View

16.

Eifler J, Feng Z, Lin B, Partin M, Humphreys E, Han M . An updated prostate cancer staging nomogram (Partin tables) based on cases from 2006 to 2011. BJU Int. 2012; 111(1):22-9. PMC: 3876476. DOI: 10.1111/j.1464-410X.2012.11324.x. View

17.

Moreira-Barbosa C, Barros-Silva D, Costa-Pinheiro P, Torres-Ferreira J, Constancio V, Freitas R . Comparing diagnostic and prognostic performance of two-gene promoter methylation panels in tissue biopsies and urines of prostate cancer patients. Clin Epigenetics. 2018; 10(1):132. PMC: 6206889. DOI: 10.1186/s13148-018-0564-2. View

18.

Pierconti F, Martini M, Pinto F, Cenci T, Capodimonti S, Calarco A . Epigenetic silencing of SOCS3 identifies a subset of prostate cancer with an aggressive behavior. Prostate. 2010; 71(3):318-25. DOI: 10.1002/pros.21245. View

19.

Kang G, Lee S, Lee H, Hwang K . Aberrant CpG island hypermethylation of multiple genes in prostate cancer and prostatic intraepithelial neoplasia. J Pathol. 2004; 202(2):233-40. DOI: 10.1002/path.1503. View

20.

Filella X, Fernandez-Galan E, Fernandez Bonifacio R, Foj L . Emerging biomarkers in the diagnosis of prostate cancer. Pharmgenomics Pers Med. 2018; 11:83-94. PMC: 5961643. DOI: 10.2147/PGPM.S136026. View